Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) tumbled 86% in early trading hours on first trading session of the week, following the Tustin, Calif., firm reported that it was carrying out an assessment of its Phase II trial for its medicine bavituximab for non-small cell lung cancer.
The firm reported that it found out huge inconsistencies between some patient sample test outcomes and patient therapy code assignments.
Investors should not depend on old studied clinical data revealed from this Phase II trial at this time, according to the company.
Its competitors include Amgen, Inc. (NASDAQ:AMGN) that surged +1.13% to $82.96 with the total traded volume of 1.66 million shares and Merck & Co., Inc. (NYSE:MRK) that increased +0.56% to $45.16 with the total traded volume of 10.91 million shares.
Other Healthcare stocks with bullish trend include Pfizer Inc. (NYSE:PFE) up +1.00% to $24.76, Tenet Healthcare Corporation(NYSE:THC) up +3.07% to $6.37 and Merck & Co., Inc.(NYSE:MRK) up +0.60% to $45.18, whereas with bearish trend include Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) down -36.44% to $19.15, Hemispherx BioPharma, Inc(NYSEAMEX:HEB) down -6.00% to $0.94 and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) down -4.09% to $8.68.
Peregrine Pharmaceuticals (NASDAQ:PPHM) stock reports on Sep 24, 2012 decreased -75.88% to the trading price of $1.30. Its fifty two week range is $0.39-$5.50. The total market capitalization remained $134.41 million.
The overall volume in the current trading session is 57.81 million shares. In its share capital PPHM has 104.19 million outstanding shares among them 95.89 million shares have been floated in market exchange. PPHM stock institutional ownership remained 6.99% while insider ownership included 0.18%.
PPHM is ahead its 52 week low with +217.95% and lagging behind from its 52 week high price with -77.45%. PPHM last month stock price volatility remained 16.01%. The stock price of PPHM is moving down from its 20 days moving average with -65.48% and remote negatively from 50 days moving average with -52.52%.
PPHM current year earnings per share experienced an addition with 10.15% while its current quarter performance remained +1046.81%. Company’s beta coefficient included 0.97. Beta factors measures the amount of market risk associated with market trade.
DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL